10-Feb-2026
No headlines found.
PRNewswire (Mon, 12-Jan 7:00 AM ET)
PRNewswire (Wed, 10-Dec 7:00 AM ET)
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
PRNewswire (Mon, 17-Nov 5:43 PM ET)
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
PRNewswire (Thu, 13-Nov 4:05 PM ET)
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
PRNewswire (Tue, 11-Nov 7:00 AM ET)
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Cytosorbents trades on the NASDAQ stock market under the symbol CTSO.
As of February 10, 2026, CTSO stock price was flat at $0.67 with 19,551 million shares trading.
CTSO has a beta of 0.86, meaning it tends to be less sensitive to market movements. CTSO has a correlation of 0.05 to the broad based SPY ETF.
CTSO has a market cap of $42.05 million. This is considered a Sub-Micro Cap stock.
Last quarter Cytosorbents reported $9 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-458,400 and exceeded earnings estimates by $.01.
In the last 3 years, CTSO traded as high as $4.29 and as low as $.60.
The top ETF exchange traded funds that CTSO belongs to (by Net Assets): VTI, VXF, IWC, MSSM.
CTSO has underperformed the market in the last year with a price return of -32.3% while the SPY ETF gained +15.6%. CTSO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.2% and -1.0%, respectively, while the SPY returned +1.9% and -0.5%, respectively.
CTSO support price is $.64 and resistance is $.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTSO shares will trade within this expected range on the day.
